We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

109 hedge funds and large institutions have $188M invested in Enzo Biochem, Inc. in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more capital invested

Capital invested by funds: $121M → $188M (+$66.5M)

22% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 32

8% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 13

2% less funds holding

Funds holding: 111109 (-2)

Holders
109
Holders Change
-2
Holders Change %
-1.8%
% of All Funds
2.73%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
14
Increased
39
Reduced
32
Closed
13
Calls
$367K
Puts
Net Calls
+$367K
Net Calls Change
-$90K
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$1.42M +$170K +26,688 +15%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$1.41M +$4.13K +648 +0.3%
Russell Investments Group
28
Russell Investments Group
United Kingdom
$1.07M +$988K +154,782 New
BIM
29
BlackRock Investment Management
Delaware
$1.05M +$2.32K +363 +0.2%
Morgan Stanley
30
Morgan Stanley
New York
$1.05M +$646K +101,168 +204%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$1.04M +$61.9K +9,705 +7%
OSAM
32
O'Shaughnessy Asset Management
Connecticut
$903K -$103K -16,076 -11%
Goldman Sachs
33
Goldman Sachs
New York
$878K +$92.1K +14,425 +13%
EGA
34
Eagle Global Advisors
Texas
$779K +$85.5K +13,400 +14%
TA
35
Teachers Advisors
New York
$777K +$270K +42,302 +61%
Two Sigma Investments
36
Two Sigma Investments
New York
$748K -$337K -52,849 -33%
Charles Schwab
37
Charles Schwab
California
$730K
Millennium Management
38
Millennium Management
New York
$705K -$567K -88,794 -47%
SIM
39
Spark Investment Management
New York
$680K -$184K -28,900 -23%
SO
40
STRS Ohio
Ohio
$673K -$137K -21,431 -18%
NFA
41
Nationwide Fund Advisors
Ohio
$609K +$397K +62,271 +245%
WCM
42
Wedge Capital Management
North Carolina
$582K
PA
43
Perceptive Advisors
New York
$582K +$107K +16,780 +25%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$567K -$13.4K -2,100 -3%
CCM
45
Corsair Capital Management
New York
$565K -$13K -2,040 -2%
Barclays
46
Barclays
United Kingdom
$548K -$39.2K -6,144 -7%
KCM
47
Kempner Capital Management
Texas
$486K
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$416K +$383K +59,969 New
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$395K
ZIM
50
Zacks Investment Management
Illinois
$387K -$740K -115,959 -68%

ENZ Hedge Fund Activity: Q4 2016 in Review

109 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2016, worth a combined $188M — up 55% from $121M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ENZ positions and 13 closed out — a net gain of 1 holder — while 39 added to existing stakes and 32 trimmed.

The largest buyer was Putnam Investments, opening a new position worth an estimated $2.07M. The largest seller was Granahan Investment Management, exiting entirely with an estimated $4.45M sold.

  • 109 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2016, down from 111 in Q3 2016.
  • Funds reported $188M of Enzo Biochem, Inc. stock for Q4 2016, up 55% quarter-over-quarter.
  • 14 funds opened new Enzo Biochem, Inc. positions in Q4 2016 and 13 closed out, a net change of +1 holder.
  • The largest Enzo Biochem, Inc. buyer in Q4 2016 was Putnam Investments, an estimated $2.07M added.
  • The largest Enzo Biochem, Inc. seller in Q4 2016 was Granahan Investment Management, an estimated $4.45M sold.

Based on aggregated 13F filings for Q4 2016.